UA75656C2 - Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture - Google Patents

Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture Download PDF

Info

Publication number
UA75656C2
UA75656C2 UA20031211971A UA20031211971A UA75656C2 UA 75656 C2 UA75656 C2 UA 75656C2 UA 20031211971 A UA20031211971 A UA 20031211971A UA 20031211971 A UA20031211971 A UA 20031211971A UA 75656 C2 UA75656 C2 UA 75656C2
Authority
UA
Ukraine
Prior art keywords
crystalline
precipitate
gatifloxacin
fatty acid
specified
Prior art date
Application number
UA20031211971A
Other languages
English (en)
Ukrainian (uk)
Inventor
Krishnaswamy S Raghavan
Sunanda A Ranadive
Kenneth S Bembenek
Richard G Corrao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UA75656C2 publication Critical patent/UA75656C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
UA20031211971A 2001-06-20 2002-10-05 Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture UA75656C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29962501P 2001-06-20 2001-06-20
PCT/US2002/014596 WO2003000175A2 (en) 2001-06-20 2002-05-10 Pediatric formulation of gatifloxacin

Publications (1)

Publication Number Publication Date
UA75656C2 true UA75656C2 (en) 2006-05-15

Family

ID=23155586

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20031211971A UA75656C2 (en) 2001-06-20 2002-10-05 Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture

Country Status (29)

Country Link
US (1) US6589955B2 (no)
EP (1) EP1406572A4 (no)
JP (1) JP4617475B2 (no)
KR (1) KR100888519B1 (no)
CN (1) CN1264514C (no)
AR (1) AR034483A1 (no)
AU (1) AU2002345534B2 (no)
BG (1) BG108444A (no)
BR (1) BR0209692A (no)
CA (1) CA2450742A1 (no)
CZ (1) CZ20033487A3 (no)
EE (1) EE200400018A (no)
GE (1) GEP20053610B (no)
HR (1) HRP20031027A2 (no)
HU (1) HUP0401497A2 (no)
IL (1) IL158863A0 (no)
IS (1) IS7048A (no)
MX (1) MXPA03011451A (no)
NO (1) NO20035605D0 (no)
NZ (1) NZ529611A (no)
PE (1) PE20030126A1 (no)
PL (1) PL366559A1 (no)
RU (1) RU2288218C2 (no)
SK (1) SK14152003A3 (no)
TW (1) TWI224004B (no)
UA (1) UA75656C2 (no)
WO (1) WO2003000175A2 (no)
YU (1) YU100303A (no)
ZA (1) ZA200309173B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370729T3 (es) 2004-05-11 2011-12-22 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan.
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070051418A1 (en) * 2005-09-02 2007-03-08 Rowles Brian A Multilayer tubes
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
CA2773033C (en) 2009-09-04 2016-10-11 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
WO2018129079A1 (en) * 2017-01-03 2018-07-12 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO88836A2 (ro) 1983-10-11 1986-03-31 Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
IT1255792B (it) 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5407921A (en) 1993-07-01 1995-04-18 Kao Corporation Method for suppressing bitter taste
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた8−アルコキシキノロンカルボン酸水和物並びにその製造方法
DE19633480A1 (de) 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2227314A1 (en) * 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
IL147242A0 (en) 1999-07-14 2002-08-14 Schering Plough Ltd Taste masking of oral quinolone liquid preparations using ion exchange resins

Also Published As

Publication number Publication date
JP4617475B2 (ja) 2011-01-26
NO20035605D0 (no) 2003-12-16
HRP20031027A2 (en) 2005-10-31
IS7048A (is) 2003-11-20
US20030028025A1 (en) 2003-02-06
TWI224004B (en) 2004-11-21
JP2005500306A (ja) 2005-01-06
YU100303A (sh) 2006-08-17
RU2003136068A (ru) 2005-02-10
US6589955B2 (en) 2003-07-08
KR20040011543A (ko) 2004-02-05
MXPA03011451A (es) 2004-04-05
ZA200309173B (en) 2005-02-25
CZ20033487A3 (cs) 2004-05-12
PL366559A1 (en) 2005-02-07
RU2288218C2 (ru) 2006-11-27
SK14152003A3 (sk) 2004-06-08
EE200400018A (et) 2004-04-15
EP1406572A4 (en) 2005-05-25
CA2450742A1 (en) 2003-01-03
BR0209692A (pt) 2004-04-20
KR100888519B1 (ko) 2009-03-11
NZ529611A (en) 2006-02-24
EP1406572A2 (en) 2004-04-14
IL158863A0 (en) 2004-05-12
WO2003000175A3 (en) 2003-04-10
CN1264514C (zh) 2006-07-19
WO2003000175A2 (en) 2003-01-03
HUP0401497A2 (hu) 2004-12-28
BG108444A (en) 2004-08-31
AU2002345534B2 (en) 2007-07-12
PE20030126A1 (es) 2003-02-08
GEP20053610B (en) 2005-09-12
AR034483A1 (es) 2004-02-25
CN1518449A (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
RU2126257C1 (ru) Фармацевтическая композиция со сниженным горьким вкусом, содержащая азалид, и способ лечения бактериальной инфекции у млекопитающих (варианты)
DK168934B1 (da) Lægemiddeladsorbater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende adsorbaterne
CA2377916C (en) Taste masked pharmaceutical liquid formulations
CA2703971C (en) Stabilized pediatric suspension of carisbamate
RU2241460C2 (ru) Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом
EP0293885A2 (en) Antibiotic-polymer compositions
UA75656C2 (en) Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture
US5460829A (en) Pharmaceutical compositions based on ebastine or analogues thereof
JP3465820B2 (ja) トロバフロキサシン経口懸濁剤
JP7403647B2 (ja) レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
AU2002345534A1 (en) Pediatric formulation of gatifloxacin
BR112014001530B1 (pt) Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma
US4772589A (en) Etoposide solution in NMP
JP6196730B2 (ja) セファロスポリンエステルを含む粒状固形製剤およびその製造方法
EP2558079B1 (en) Ciprofloxacin dry syrup composition
MXPA00005554A (en) Trovafloxacin oral suspensions
JPH04221379A (ja) チアプロフェン酸又はその不溶性若しくは部分可溶性エステルとシクロデキストリン又はそれらの誘導体との新規な複合体
WO1995023603A1 (de) Verwendung von in 6-stellung substituierten 2-amino-4,5,7,8-tetrahydro-6h-thiazolo 5,4-d azepinen als antidepressiva